Anthem Blue Cross

Prior authorization requirements for Part B drugs: Azedra (iobenguane I 131) and Poteligeo (mogamulizumab)

On November 1, 2018, Anthem Blue Cross prior authorization (PA) requirements will change for Part B Injectable/Infusible drugs covered by Anthem. The drugs Azedra (iobenguane I 131) and Poteligeo (mogamulizumab). Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims.

Prior authorization requirements will be added to the following part B drugs:

- Azedra (iobenguane I 131): for treatment of malignant pheochromocytoma and paraganglioma. [J3490, J9999]
- Poteligeo (mogamulizumab): for treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy. [J3490, J9999]

Please note, the above drugs are currently billed under the Not Otherwise Classified (NOC) HCPCS code [J3490, J9999]; it is unlisted, because no J code has been established at this time. Since these codes include all drugs that are NOC, if the authorization is denied for medical necessity, the plan’s denial will be for the drug and not the HCPCS code.

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the Provider Self-Service Tool at www.Availity.com. Contracted and non-contracted providers who are unable to access Availity may call our Provider Services at the number on the back of the member’s ID card for prior authorization requirements.

72238MUSENMUB 05/22/18

Anthem Blue Cross is the trade name of Blue Cross of California. Independent licensee of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.